• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    9/26/23 5:31:27 PM ET
    $ADIL
    $BCLI
    $DMK
    $FEMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADIL alert in real time by email

    Gainers

    • Galecto (NASDAQ:GLTO) stock increased by 40.3% to $0.81 during Tuesday's after-market session. At the close, Galecto's trading volume reached 3.6 million shares. This is 790.3% of its average volume over the last 100 days. The company's market cap stands at $21.8 million.
    • Exagen (NASDAQ:XGN) stock increased by 15.76% to $2.79. The market value of their outstanding shares is at $47.0 million.
    • MSP Recovery (NASDAQ:LIFW) stock moved upwards by 13.87% to $0.17. MSP Recovery's trading volume hit 5.6 million shares by close, accounting for 18.3% of its average volume over the last 100 days. The company's market cap stands at $57.3 million.
    • Brainstorm Cell (NASDAQ:BCLI) stock rose 10.96% to $0.43. At the close, Brainstorm Cell's trading volume reached 325.2K shares. This is 97.6% of its average volume over the last 100 days. The market value of their outstanding shares is at $19.5 million.
    • VYNE Therapeutics (NASDAQ:VYNE) stock increased by 9.62% to $3.76. The market value of their outstanding shares is at $12.3 million.
    • Freeline Therapeutics (NASDAQ:FRLN) stock increased by 9.24% to $4.16. The company's market cap stands at $18.1 million.

    Losers

    • Minerva Surgical (NASDAQ:UTRS) shares decreased by 23.5% to $0.22 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 1.5 million shares, which is 465.5 percent of its average volume over the last 100 days. The company's market cap stands at $38.3 million.
    • Femasys (NASDAQ:FEMY) stock fell 16.22% to $1.24. Femasys's trading volume hit 29.0 million shares by close, accounting for 761.5% of its average volume over the last 100 days. The company's market cap stands at $18.6 million.
    • DMK Pharmaceuticals (NASDAQ:DMK) stock decreased by 15.25% to $0.65. Today's trading volume for this security ended up closing at 1.4 million shares, which is 890.0 percent of its average volume over the last 100 days. The company's market cap stands at $6.0 million.
    • Adial Pharmaceuticals (NASDAQ:ADIL) shares declined by 11.58% to $2.75. The market value of their outstanding shares is at $3.3 million.
    • Tharimmune (NASDAQ:THAR) shares declined by 11.19% to $0.26. Trading volume for this security closed at 13.2 million, accounting for 3742.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $4.5 million.
    • SeqLL (NASDAQ:SQL) shares decreased by 10.41% to $16.53. The company's market cap stands at $6.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADIL
    $BCLI
    $DMK
    $FEMY

    CompanyDatePrice TargetRatingAnalyst
    Galecto Inc.
    $GLTO
    2/17/2026$45.00Buy
    UBS
    Galecto Inc.
    $GLTO
    1/7/2026$46.00Outperform
    Leerink Partners
    Galecto Inc.
    $GLTO
    12/1/2025$32.00Buy
    Guggenheim
    Femasys Inc.
    $FEMY
    11/20/2025$6.50Buy
    Laidlaw
    Exagen Inc.
    $XGN
    9/11/2025$15.00Buy
    B. Riley Securities
    VYNE Therapeutics Inc.
    $VYNE
    7/31/2025Buy → Neutral
    BTIG Research
    Exagen Inc.
    $XGN
    7/30/2025$12.00Sector Weight → Overweight
    KeyBanc Capital Markets
    Exagen Inc.
    $XGN
    7/23/2025$12.00Buy
    Craig Hallum
    More analyst ratings

    $ADIL
    $BCLI
    $DMK
    $FEMY
    SEC Filings

    View All

    Femasys Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - FEMASYS INC (0001339005) (Filer)

    4/1/26 9:13:11 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form S-4 filed by VYNE Therapeutics Inc.

    S-4 - VYNE Therapeutics Inc. (0001566044) (Filer)

    3/31/26 5:28:34 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Brainstorm Cell Therapeutics Inc.

    10-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

    3/31/26 5:26:31 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADIL
    $BCLI
    $DMK
    $FEMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Zeronda Tyler

    4 - VYNE Therapeutics Inc. (0001566044) (Issuer)

    4/2/26 4:15:23 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Stuart Iain

    4 - VYNE Therapeutics Inc. (0001566044) (Issuer)

    4/2/26 4:15:19 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Harsch Mutya

    4 - VYNE Therapeutics Inc. (0001566044) (Issuer)

    4/2/26 4:15:14 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $BCLI
    $DMK
    $FEMY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth

    ATLANTA, April 01, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of John Canning as Chief Operating Officer. Mr. Canning is an accomplished medical device executive with more than 25 years of experience leading global operations and technology organizations within complex medical device companies. He brings a track record of scaling organizations, advancing product pipelines, and driving operational excellence across key functions to support commercial growth and product adoption. Prior to joining

    4/1/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

    ATLANTA, March 31, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the year ended December 31, 2025 and provides a corporate update. Corporate Highlights from 4Q 2025 to date Initiated patient enrollment in the FINALE pivotal clinical trial evaluating FemBloc, advancing toward U.S. approval.Appointed Kenneth D. Eichenbaum, M.D., M.S.E., to the Board of Directors, strengthening leadership and strategic oversight.FemBloc permanent birth control system achieved certification under the Medical Device Single Au

    3/31/26 4:05:00 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update

    Strategic $2.0 million post year-end financing and re-rating of BCLI shares underscore market confidenceCompany highlights durable long-term survival in Expanded Access Program (EAP) cohort supporting Phase 3b patient selection and inclusion criteriaNEW YORK, March 31, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2025, and provided a corporate update. "Our main priority continues to be advancing NurOwn

    3/31/26 4:01:00 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADIL
    $BCLI
    $DMK
    $FEMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS initiated coverage on Galecto with a new price target

    UBS initiated coverage of Galecto with a rating of Buy and set a new price target of $45.00

    2/17/26 8:59:23 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Galecto with a new price target

    Leerink Partners initiated coverage of Galecto with a rating of Outperform and set a new price target of $46.00

    1/7/26 8:34:02 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Galecto with a new price target

    Guggenheim initiated coverage of Galecto with a rating of Buy and set a new price target of $32.00

    12/1/25 8:28:46 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $BCLI
    $DMK
    $FEMY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman Gravitas Capital Lp bought $500,000 worth of shares (337,838 units at $1.48), increasing direct ownership by 86% to 732,424 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 9:29:23 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Parikh Sanam bought $1,450 worth of shares (1,000 units at $1.45), increasing direct ownership by 130% to 1,770 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 7:34:56 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Appajosyula Sireesh bought $90,973 worth of shares (61,496 units at $1.48), increasing direct ownership by 1,824% to 64,868 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 7:31:11 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $BCLI
    $DMK
    $FEMY
    Leadership Updates

    Live Leadership Updates

    View All

    Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth

    ATLANTA, April 01, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of John Canning as Chief Operating Officer. Mr. Canning is an accomplished medical device executive with more than 25 years of experience leading global operations and technology organizations within complex medical device companies. He brings a track record of scaling organizations, advancing product pipelines, and driving operational excellence across key functions to support commercial growth and product adoption. Prior to joining

    4/1/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

    ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of Kenneth D. Eichenbaum, M.D., M.S.E., to its Board of Directors. Dr. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital, bringing deep clinical expertise and strategic insight developed through more than 20 years of evaluating biotechnology and medical device companies and advising investment firms. He completed a fel

    3/18/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer

    Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Executive Officer, as Chairman of the Board and approved the appointment of Angela Radkowski as Chief Operating Officer, effective February 5, 2026. Mr. Wendland succeeds Vincent LoPriore, wh

    2/6/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $BCLI
    $DMK
    $FEMY
    Financials

    Live finance-specific insights

    View All

    Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

    ATLANTA, March 31, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the year ended December 31, 2025 and provides a corporate update. Corporate Highlights from 4Q 2025 to date Initiated patient enrollment in the FINALE pivotal clinical trial evaluating FemBloc, advancing toward U.S. approval.Appointed Kenneth D. Eichenbaum, M.D., M.S.E., to the Board of Directors, strengthening leadership and strategic oversight.FemBloc permanent birth control system achieved certification under the Medical Device Single Au

    3/31/26 4:05:00 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

    CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 2025, before the market opens on Tuesday, March 10, 2026. John Aballi, President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT). Conference Call & Webcast: U.S. dial-in: 877-407-0890International dial-in: +1 201-389-0918Webcast: Available via the Exagen investor relations website at investors.exagen.com Replay: A telephone replay will be available until Tuesday, March 24, 2026: U.

    2/24/26 9:00:00 AM ET
    $XGN
    Medical Specialities
    Health Care

    VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement

    Following closing, combined company plans to progress Yarrow's lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor ("TSHR") antibody for Graves' disease ("GD") and thyroid eye disease ("TED")Yarrow Bioscience is the seventh biotechnology company founded by RTW Investments and plans to advance in-licensed asset YB-101 (also known as GS-098) into a U.S.-based Phase 1b/2b trial in patients with GD in the first half of 2026; a Phase 1 trial in TED is being conducted in China by partner Changchun GeneScience Pharmaceutical Co., Ltd ("GenSci")Pre-closing private financings totaling approximately $200 million expected to fund operations into 2028Companies to

    12/17/25 8:00:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $BCLI
    $DMK
    $FEMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Exagen Inc.

    SC 13G/A - EXAGEN INC. (0001274737) (Subject)

    12/12/24 5:00:54 PM ET
    $XGN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Adial Pharmaceuticals Inc

    SC 13G/A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)

    11/14/24 3:44:01 PM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care